not yet tested for prostate cancer (I think) but still…
“But two years after starting a treatment regimen that combined ruxolitinib with the checkpoint inhibitor nivolumab—a current standard of care—87% of patients were still alive, and 46% stopped exhibiting signs of cancer progression altogether.”
excellent! Knowing the pathways of resistance mechanisms of action and the drugs to stop those pathways is important! Now start combining already approved drugs is a fast way to better outcomes.
Here’s a summary by AI (check for mistakes) of the key points from the web page:
New Cancer Treatment Method: Scripps Research scientists discovered that combining ruxolitinib with checkpoint inhibitors enhances T-cell responses, improving cancer treatment, particularly for Hodgkin lymphoma.
Clinical Trial Success: A phase I clinical trial showed that 87% of patients were still alive after two years, and 46% showed no signs of cancer progression, indicating a potential breakthrough in immunotherapy.
Myeloid Cells Role: The combination therapy also reduced myeloid suppressor cells and neutrophil-to-lymphocyte ratios, which are indicators of poor prognosis in several cancers, including Hodgkin lymphoma.
Future Research Plans: Researchers aim to test other JAK inhibitors and plan clinical trials for other cancer types, hoping to apply this method to various immunotherapy-resistant cancers.
Darolutamide and mCRPC...New Promising Drug
Promising new treatment for CRPC
A promising article. 
Antigen vaccine trial is promising. 
